Monica Hellesøy

554 total citations
20 papers, 150 citations indexed

About

Monica Hellesøy is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Monica Hellesøy has authored 20 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Immunology and 8 papers in Oncology. Recurrent topics in Monica Hellesøy's work include Phagocytosis and Immune Regulation (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Acute Myeloid Leukemia Research (6 papers). Monica Hellesøy is often cited by papers focused on Phagocytosis and Immune Regulation (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Acute Myeloid Leukemia Research (6 papers). Monica Hellesøy collaborates with scholars based in Norway, United States and Denmark. Monica Hellesøy's co-authors include James B. Lorens, Bjørn Tore Gjertsen, Anna Blois, David Micklem, Crina Tiron, Lars A. Akslen, Jacques E. Nör, André Sulen, Tim Grob and Peter J.M. Valk and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Monica Hellesøy

19 papers receiving 149 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monica Hellesøy Norway 7 57 37 35 34 32 20 150
Neha U. Patel United States 9 77 1.4× 27 0.7× 9 0.3× 12 0.4× 10 0.3× 12 274
Heli Salminen‐Mankonen Finland 6 97 1.7× 33 0.9× 12 0.3× 33 1.0× 9 0.3× 7 245
Florence Zylbersztejn France 8 79 1.4× 18 0.5× 55 1.6× 12 0.4× 5 0.2× 8 153
Daniel Kohnen United States 4 96 1.7× 82 2.2× 91 2.6× 38 1.1× 33 1.0× 12 210
Kyle B. Woodward United States 7 59 1.0× 86 2.3× 19 0.5× 41 1.2× 19 0.6× 14 334
Yunshu Che China 9 172 3.0× 44 1.2× 10 0.3× 16 0.5× 9 0.3× 16 284
Fatemeh Alikarami‬ Iran 9 107 1.9× 12 0.3× 28 0.8× 10 0.3× 5 0.2× 15 179
Omid Shah United States 6 53 0.9× 52 1.4× 21 0.6× 17 0.5× 6 0.2× 7 197
Laura A. Paganessi United States 6 62 1.1× 42 1.1× 90 2.6× 6 0.2× 10 0.3× 13 194
Kwang‐Soo Kim United States 5 171 3.0× 60 1.6× 88 2.5× 38 1.1× 6 0.2× 7 288

Countries citing papers authored by Monica Hellesøy

Since Specialization
Citations

This map shows the geographic impact of Monica Hellesøy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica Hellesøy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica Hellesøy more than expected).

Fields of papers citing papers by Monica Hellesøy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monica Hellesøy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica Hellesøy. The network helps show where Monica Hellesøy may publish in the future.

Co-authorship network of co-authors of Monica Hellesøy

This figure shows the co-authorship network connecting the top 25 collaborators of Monica Hellesøy. A scholar is included among the top collaborators of Monica Hellesøy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica Hellesøy. Monica Hellesøy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruokoranta, Tanja, Joseph Saad, Monica Hellesøy, et al.. (2023). Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia. Blood. 142(Supplement 1). 2927–2927.
2.
Hellesøy, Monica, et al.. (2021). Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 15(9). 2285–2299. 7 indexed citations
3.
Hellesøy, Monica, Tim Grob, Adil Al Hinai, et al.. (2021). FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 15(9). 2300–2317. 6 indexed citations
4.
Hellesøy, Monica, et al.. (2020). Single Cell Detection of the p53 Protein by Mass Cytometry. Cancers. 12(12). 3699–3699. 5 indexed citations
5.
Hellesøy, Monica, André Sulen, Reidun Kristin Kopperud, et al.. (2019). Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 145(7). 1729–1749. 8 indexed citations
6.
Hellesøy, Monica, et al.. (2019). Titrating Complex Mass Cytometry Panels. Cytometry Part A. 95(7). 792–796. 14 indexed citations
7.
Gjertsen, Bjørn Tore, et al.. (2019). Early response evaluation in AML using mass cytometry. HemaSphere. 3(S2). 3–5. 3 indexed citations
8.
Majumder, Muntasir Mamun, Aino‐Maija Leppä, Monica Hellesøy, et al.. (2019). Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica. 105(6). 1527–1538. 16 indexed citations
9.
Loges, Sonja, Michael Heuser, Jörg Chromik, et al.. (2019). First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.. Journal of Clinical Oncology. 37(15_suppl). 7043–7043. 6 indexed citations
10.
Blaser, Nello, Monica Hellesøy, Jørn Skavland, et al.. (2018). A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy. Blood. 132(Supplement 1). 1502–1502. 1 indexed citations
11.
Majumder, Muntasir Mamun, Monica Hellesøy, Paul Dowling, et al.. (2018). Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood. 132(Supplement 1). 264–264. 1 indexed citations
12.
13.
Hellesøy, Monica, Håkon Reikvam, Sonja Loges, et al.. (2016). Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood. 128(22). 3995–3995. 1 indexed citations
14.
Gausdal, Gro, et al.. (2016). Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. Cancer Immunology Research. 4(1_Supplement). B014–B014. 2 indexed citations
15.
Gausdal, Gro, Jing Kang, Agnete S. T. Engelsen, et al.. (2016). Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. Cancer Research. 76(14_Supplement). 566–566. 4 indexed citations
16.
Hellesøy, Monica & James B. Lorens. (2015). Cellular context–mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Molecular Biology of the Cell. 26(14). 2698–2711. 10 indexed citations
17.
Hellesøy, Monica, Anna Blois, Crina Tiron, et al.. (2014). Akt1 Activity Regulates Vessel Maturation in a Tissue Engineering Model of Angiogenesis. Tissue Engineering Part A. 20(19-20). 2590–2603. 3 indexed citations
18.
Tiron, Crina, Gro Gausdal, Tone Sandal, et al.. (2014). Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. Cancer Research. 74(19_Supplement). 1747–1747. 12 indexed citations
19.
Gausdal, Gro, Tone Sandal, Stefan Hinz, et al.. (2014). Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.. Clinical Cancer Research. 20(2_Supplement). B30–B30. 1 indexed citations
20.
Blois, Anna, Crina Tiron, Monica Hellesøy, et al.. (2010). Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine. 5(4). e52–e62. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neha U. Patel Breakdown of academic impact, for papers by Heli Salminen‐Mankonen Breakdown of academic impact, for papers by Florence Zylbersztejn Breakdown of academic impact, for papers by Daniel Kohnen Breakdown of academic impact, for papers by Kyle B. Woodward Breakdown of academic impact, for papers by Yunshu Che Breakdown of academic impact, for papers by Fatemeh Alikarami‬ Breakdown of academic impact, for papers by Omid Shah Breakdown of academic impact, for papers by Laura A. Paganessi Breakdown of academic impact, for papers by Kwang‐Soo Kim
Rankless by CCL
2026